SEC Company Response from SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Apr 17, 2007
SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: April 17, 2007 · CIK: 0000812796 · Accession: 0000812796-07-000037
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-141209
Letter
DOR BioPharma, Inc.
Brickell Avenue, Suite 701-S
Miami, Florida 33131
April 16,
VIA FACSIMILE AND EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, NE
Washington, D.C. 20549
Attention: John Krug
Re: DOR BioPharma, Inc.
Registration Statement on Form SB-2
Pre-Effective Amendment No. 1
Filed April 13, 2007
File No. 333-141209
Ladies and Gentlemen:
The undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities Act of 1933, as amended, that the Registration Statement on Form SB-2 originally filed with the Securities and Exchange Commission (the “Commission”) on March 9, 2007 (File No. 333-141209), as amended by the Pre-Effective Amendment No. 1 to the Registration Statement on Form SB-2, by DOR BioPharma, Inc. (the “Company”) be declared effective as of 3:00 p.m. Eastern Time on Wednesday, April 18, 2007, or as soon thereafter as possible.
The undersigned hereby acknowledges that (i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
DOR
BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
DOR
BioPharma,
Inc.
1101
Brickell Avenue, Suite 701-S
Miami,
Florida 33131
April
16,
2007
VIA
FACSIMILE AND EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F
Street, NE
Washington,
D.C. 20549
Attention:
John Krug
Re: DOR
BioPharma, Inc.
Registration
Statement on Form SB-2
Pre-Effective
Amendment No. 1
Filed
April 13, 2007
File
No. 333-141209
Ladies
and Gentlemen:
The
undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities
Act of 1933, as amended, that the Registration Statement on Form SB-2 originally
filed with the Securities and Exchange Commission (the “Commission”) on March 9,
2007 (File No. 333-141209), as amended by the Pre-Effective Amendment No. 1
to
the Registration Statement on Form SB-2, by DOR BioPharma, Inc. (the “Company”)
be declared effective as of 3:00 p.m. Eastern Time on Wednesday, April 18,
2007,
or as soon thereafter as possible.
The
undersigned hereby acknowledges that (i) should the Commission or the staff,
acting pursuant to delegated authority, declare the filing effective, it does
not foreclose the Commission from taking any action with respect to the filing;
(ii) the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company
from
its full responsibility for the adequacy and accuracy of the disclosure in
the
filing; and (iii) the Company may not assert the declaration of effectiveness
as
a defense in any proceeding initiated by the Commission or any person under
the
federal securities laws of the United States.
Very
truly yours,
DOR
BIOPHARMA, INC.
By:/s/
Christopher J. Schaber
Christopher
J. Schaber
President
and Chief Executive Officer
cc: Leslie
J.
Croland, Esq.